AstraZeneca PLC (NASDAQ:AZN) is one of the stocks in focus on Jim Cramer’s game plan. Cramer mentioned the company during the ...

Q4 2025 Earnings Call February 10, 2026 6:45 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...

Carillon Tower Advisers, an investment management company, released its fourth-quarter 2025 investor letter “Carillon Eagle Growth & Income Fund”. A copy of the letter can be downloaded here. 2025 ...

Shore Capital downgraded AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) to 'hold' from 'buy', citing a less favourable earnings ...

AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) delivered strong full-year results for 2025, driven by solid commercial performance ...

AstraZeneca Plc expects profit to grow further this year, boosted by sales of its cancer drugs as it works to offset a patent ...

Investors in AstraZeneca PLC ( LON:AZN ) had a good week, as its shares rose 6.6% to close at UK£149 following ...

AstraZeneca Plc’s playbook to break into the red-hot obesity market rests on improving upon existing medicines, offering ...

AstraZeneca PLC (NASDAQ:AZN) is one of the stocks Jim Cramer shed light on recently. When a caller mentioned that they are ...

AstraZeneca PLC (NASDAQ: AZN) is one of the best healthcare stocks to buy for 2026. On January 29, AstraZeneca announced a ...

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming February 21, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors ...

February 2026 Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus The US Food and Drug Administration (FDA) issued a complete response letter (CRL) ...